Peptide A · Growth-signaling analogues
Tesamorelin
Synthetic growth hormone-releasing factor analog research material
EgriftaTH9507
Open the 10 mg price board ↗Research price & evidence comparisonTesamorelin
Tesamorelin
vs Sermorelin.
Tesamorelin and sermorelin sit in the same broad growth-signaling research family but enter Peptide Local through different exact-size boards and distinct identity records. This comparison shows public US research-market prices, seller coverage, availability, evidence access, and the size mismatch that makes raw vial-price comparisons misleading.
3shared seller pages
Different10 mg / 5 mg board sizes
6rows with public evidence routes
0clinical or effect rankings
Identity before price
Two records, kept separate.
Tesamorelin is categorized as a synthetic growth hormone-releasing factor analog research material on a 10 mg board; sermorelin is categorized as a synthetic growth hormone-releasing hormone fragment research material on a 5 mg board. Their vial prices therefore require separate per-milligram normalization and still do not imply equivalence.
Peptide B · Growth-signaling analogues
Sermorelin
Synthetic growth hormone-releasing hormone fragment research material
GHRH 1-29Sermorelin acetateGeref
Open the 5 mg price board ↗Like-for-like fields
Commercial footprint, side by side.
Price ranges use rows marked in stock. “Public evidence route” means a seller exposed a document link; it does not establish authenticity, chain of custody, purity, sterility, or vial contents.
| Comparison field | Tesamorelin | Sermorelin |
|---|---|---|
| Editorial family | Growth-signaling analogues | Growth-signaling analogues |
| Seller-listed identity | Synthetic growth hormone-releasing factor analog research material | Synthetic growth hormone-releasing hormone fragment research material |
| Nominal board size | 10 mg | 5 mg |
| Available list range | $60.00–$79.19 | $43.00–$49.49 |
| Median available price | $73.00 | $46.25 |
| Lowest available / mg | $6.00 | $8.60 |
| Available rows | 4 of 5 | 2 of 3 |
| Public evidence routes | 4 rows | 2 rows |
| Evidence only on request | 1 rows | 1 rows |
| Available-price spread | 32% | 15% |
| Snapshot checked | Jul 23, 2026 | Jul 23, 2026 |
Unit warning
Per-milligram figures normalize the seller’s nominal quantity only. They are not a cross-compound value, potency, effect, or dose comparison.
Seller overlap
Where the current boards intersect.
Searchers often group the two by growth-signaling terminology, but the different catalog identities and nominal board sizes make this an important test of whether a comparison keeps units and category claims honest.
- Biotech Peptides
- Core Peptides
- Pepta Labs
- Prime Peptides
- Pure Health Peptides
No right-only seller in the qualified rows.
Three reading rules
What keeps this comparison honest.
- 01
Never compare the headline vial prices without checking the 10 mg versus 5 mg board sizes.
- 02
Per-milligram normalization corrects the unit, not differences in identity, composition, or evidence.
- 03
This page compares seller observations and does not recommend either material for personal use.
Official context boundary
Read the source behind each category note.
These official context records explain why Peptide Local keeps research listings outside medical and approved-product lanes. They do not certify any seller or material.
Tesamorelin is also the proper name of FDA-licensed Egrifta products. Those prescription biologics have specific strengths, indications, labeling, and regulated supply chains; the laboratory research listings on this page are not Egrifta and are not approval-equivalent.
Check the FDA Purple Book product record ↗FDA records show that Geref, a sermorelin acetate prescription product, was approved in 1997; FDA later documented withdrawal of its approvals after commercial discontinuation. Current research-vial listings are not that approved product or supply chain.
Read the FDA orphan-drug record ↗Continue comparing